Skip to main content
. Author manuscript; available in PMC: 2008 Feb 4.
Published in final edited form as: J Immunother. 2004;27(6):472–477. doi: 10.1097/00002371-200411000-00007

TABLE 2.

Clinical Response of Patients Receiving the NY-ESO-1 Peptide Vaccination

Peptide Alone Crossover to High-dose IL-2
Total 37 15
Partial response 1* 0
Complete response 0 0
*

One partial response in group 5, lasting 12 months.